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Abstract 
Objective: 
Plant Food Supplements (PFS) are products of increasing popularity and wide-
spread distribution. Nevertheless, information about their risks is limited. To fill 
this gap, a poisons centres-based study was performed as part of the EU 
project PlantLIBRA. 
Methods: 
Multicentre retrospective review of data from selected European and Brazilian 
poisons centres, involving human cases of adverse effects due to plants 
consumed as food or as ingredients of food supplements recorded between 
2006 and 2010. 
Results: 
10 poisons centres provided a total of 75 cases. In 57 cases (76%) a PFS was 
involved; in 18 (24%) a plant was ingested as food. The 10 most frequently 
reported plants were Valeriana officinalis, Camellia sinensis, Paullinia cupana, 
Melissa officinalis, Passiflora incarnata, Mentha piperita, Glycyrrhiza glabra, Ilex 
paraguariensis, Panax ginseng, and Citrus aurantium. The most frequently 
observed clinical effects were neurotoxicity and gastro-intestinal symptoms. 
Most cases showed a benign clinical course; however, five cases were severe. 
Conclusions: 
PFS-related adverse effects seem to be relatively infrequent issues for poisons 
centres. Most cases showed mild symptoms. Nevertheless, the occurrence of 
some severe adverse effects and the increasing popularity of PFS require 
continuous active surveillance, and further research is warranted.  
1. Introduction 
In the last two decades, the use of dietary supplements has increased 
dramatically all over the world. Changes in the legislation of medications and 
related products  lead to an expansion of the markets for dietary supplements 
and allowed more intensive marketing (Denham, 2011; Miroddi, 2013; Silano, 
2011; Vargas-Murga, 2011), resulting in a growing awareness and information 
of the population about health aspects. The rising significance of health issues 
in daily life, together with an increased possibility and tendency to self-
medicate, and the aging of the population seem to be the major reasons for the 
success of the dietary supplements (Kennedy, 2005; Peters, 2003). Additional 
factors that promote the consumption of products of plant origin include the 
belief that botanicals are natural and therefore safe and the mistrust in 
conventional medications (Egan, 2011; Lynch, 2007; Marinac, 2007). 
Food supplements with botanical ingredients, also called plant food 
supplements (PFS), cover a broad field of indications and therefore a wide 
range of plants are involved. Some preparations contain only one ingredient, 
which can consist of an extract (or concentrate) of a single plant or a specific 
plant compound (e.g. caffeine). Other PFS are a combination of several plants. 
In case of adverse effects, the complex nature of these ingredients and 
products makes it difficult to identify the causative component. 
Along with the global spreading and the increasing use of PFS, scientific 
research on these products was intensified. However, clinical data on adverse 
effects of PFS are scarce and the literature mainly consists of case reports or 
case series on single plants (Di Lorenzo, 2015). The issue of underreporting is 
particular relevant in this area and partially explains paucity of data on adverse 
effects to these products (Geller, 2015; Kennedy, 2005). 
The occurrence of some severe incidents after the intake of PFS (Palmer, 2003; 
Vassilev, 2009; Vitalone, 2011), demonstrated the need for additional studies 
on PFS-related adverse effects. For these reasons, the European Community's 
Seventh Framework Programme funded PlantLIBRA project (www.plantlibra.eu) 
also comprised research on the adverse effects profile of PFS and plants 
consumed as food (Bucchini, 2011). 
The aim of this study was to identify plants commonly involved in adverse 
reactions related to the intake of PFS and of plants consumed as food, and to 
describe the type and severity of associated signs and symptoms by analysing 
data collected by poisons centres. 
 
 
2. Methods 
2.1 Study design 
Through a multicentre retrospective review of data from European and Brazilian 
poisons centres, documented human adult and pediatric cases (children defined 
as ≤ 16 years) of adverse effects related to the intake of PFS or plants 
consumed as food were collected for the period 2006 – 2010. The inclusion of 
Brazil in a European study is due to the fact that the University of San Paulo 
was one of the extra-European PlantLIBRA partners, as required by the specific 
project call. 
 2.2 Inclusion and exclusion criteria 
The following criteria had to be met for reported cases to be included in the 
study: 
- Exposure to an agent categorized as PFS by the reporting poisons centre 
or exposure to a plant listed in an annex of the study protocol (the plant list 
can be accessed online as supplementary data, table A). This list mainly 
represents plants commonly used in PFS. 
- Symptoms/signs of an adverse effect; 
- Complete observation (i.e. medical follow-up covering the entire course of 
illness related to the exposure, until the resolution of symptoms or until 
stable presentation of sequelae); 
- Confirmed or probable causal relationship between exposure and clinical 
effect(s). Causality assessment was based on the World Health 
Organisation Uppsala Monitoring Centre (WHO-UMC) standardised case 
causality assessment criteria originally developed for the assessment of 
adverse drug reactions (WHO, 2015) and included an adequate temporal 
relationship between exposure and symptoms, absence of other exposures 
or underlying diseases that can also explain the symptoms, and the 
presence of symptoms which are described for the substance in question or 
are plausible from a toxicodynamic point of view.  
 
Exclusion criteria were: 
- Asymptomatic exposures; 
- Ingestion of the PFS/plant for other reasons than for nutrition or for a health 
benefit (e.g. child ingesting a plant accidentally; misidentification of plants); 
- Ingestion of a plant (as food), that is not on the list; 
- Ingestion outside the study period. 
 
Each case was reviewed in detail and independently assessed by an expert 
panel at the Swiss National Poisons Centre, Tox Info Suisse, consisting of a 
pharmacist with expertise in plants, and a senior clinical pharmacologist and 
toxicologist with additional qualifications in general internal medicine. Any 
disagreement in case assessment was resolved by consensus. 
 
2.3 Data collection and study population 
Poisons centres were identified and contacted using the EAPCCT network 
(European Association of Poisons Centres and Clinical Toxicologists). The 
poisons centres were required to provide anonymized data – including age, sex, 
and weight of the patient, ingested substance and, if available, dose, type of 
symptoms/signs, laboratory values and causal relationship, severity of 
symptoms and signs (graded according to the Poisoning Severity Score, PSS 
(Persson, 1998)), therapeutic interventions and, if applicable, decontamination 
procedures performed with time between ingestion and decontamination – in a 
standardized exchange spreadsheet format. Data had to be translated into 
English; however Italian, Spanish, French, and German were also accepted due 
to language competencies within the Swiss National Poisons Centre. 
66 requests for participation in the study were sent to European and Brazilian 
poisons centres. Of the 41 (62%) poisons centres who answered, 10 were able 
to provide a total of 426 cases. 351 (82%) of these had to be excluded because 
they did not meet the inclusion criteria (i.e., insufficient causal relationship 
between ingested plant/PFS and observed symptoms and signs, asymptomatic 
ingestion, product not a PFS or plant not on the list, wrong circumstances of 
ingestion (e.g. child ingesting a plant accidentally), year of occurrence not within 
the study period), leaving 75 (18%) cases of adverse effects which were 
available for analysis. 
 
2.4 Data processing and analysis 
Since not all centres classify the severity of signs and symptoms in the same 
way, the cases were re-evaluated according to the Poisoning Severity Score 
(PSS) developed by the European Association of Poisons Centres and Clinical 
Toxicologists, the International Programme on Chemical Safety, and the 
European Commission (Persson, 1998). The severity of symptoms of individual 
patients was classified as "minor" if only mild, transient and spontaneously 
resolving symptoms/signs were present, as "moderate" if at least one 
pronounced or prolonged symptom/sign was recorded, as "severe" if at least 
one severe or life-threatening symptom/sign was observed, or as "fatal", if the 
ingestion of the PFS or plant was the recorded cause of death. 
Data from the centres were merged into one single standardized Excel 
spreadsheet (Microsoft Excel 2010, Microsoft Corporation, Redmond, USA) and 
categorized into age groups, type of product, organ system involved, and 
severity of symptoms and signs. For the analyses of the relationships between 
PFS/plants and symptoms/signs, data were exported into an Access database 
(Microsoft Access 2010, Microsoft Corporation, Redmond, USA). Descriptive 
statistics were used to analyze grouped data. 
 
2.5 Ethical approval 
No ethics approval was required for this study according to a statement of the 
cantonal ethics committee Zurich. Each of the participating poisons centres was 
required to investigate whether or not a local ethics committee/institutional 
review board approval was required. The answers, and if applicable the local 
ethics committee approval, were transmitted to the Swiss National Poisons 
Centre, Tox Info Suisse. The procedure was surveyed by the ethics advisor of 
the PlantLIBRA project. 
 
2.6 Data protection issues 
Analyses were performed with completely anonymized data. Information was 
accessed and handled by study members only. 
 
 
3. Results 
3.1 Patient characteristics and severity of signs and symptoms 
The 75 cases included in the study originated from all over Europe (Finland 9 
cases, France 31, Germany 4, Italy 13, Serbia 4, Sweden 5, Switzerland 5) and 
Brazil (4). Demographic characteristics of the patients were as follows: 68 
adults (91%) with a mean age of 41.7 years (SD 18.8, median 40.0, range 16-
92; age unknown in six cases) and seven children (9%) with a mean age of 11.4 
years (SD 5.4, median 15, range 2-15). Both genders were almost equally 
represented among adults and children, in total there were 41 females (55%) 
and 34 males (45%). 
Most cases showed a benign clinical course (table 1). Children mainly 
developed minor signs and symptoms, and there were no severe cases among 
this age group. Adults older than 65 showed a tendency towards more 
moderate and severe clinical courses compared to younger patients. No fatal 
outcome was observed. 
 
3.2 Involved plants/PFS and severity of signs and symptoms 
In 57 cases (76%) a PFS was involved, and in 18 (24%) a plant was ingested 
as food (table 1). The number of involved PFS containing only one ingredient 
("PFS mono") was comparable to that with more than one ingredient ("PFS 
multi"). PFS with more than one ingredient were more frequently associated 
with moderate and severe clinical courses (33.3%) compared to PFS with only 
one ingredient (10.0%). 
Plants, as ingredients of PFS or consumed as food, involved in three or more 
cases are listed in table 2. Plants most commonly ingested as PFS were 
Valeriana officinalis L., Camellia sinensis (L.) Kuntze, Paullinia cupana Kunth, 
Melissa officinalis L., and Mentha piperita L.; plants most commonly consumed 
as food were Glycyrrhiza glabra L., Cynara scolymus L., Allium ursinum L., and 
Taraxacum officinale L.. The severity of signs and symptoms in relation to all 
plants involved in the cases of adverse effects due to the ingestion of a PFS or 
a plant consumed as food is shown in table 3. 
 
3.3 Organ systems involved and observed signs and symptoms 
3.3.1 General evaluation 
In 59 (79%) of the 75 patients only one organ/organ system was involved; 14 
patients had two organs/systems involved, and two patients had more than two 
organs/systems involved. The most frequently involved organ system was the 
nervous system (n = 34), followed by the gastrointestinal system (n = 27), the 
cardiovascular system (n = 13), skin/mucosa (n = 8), the liver (n = 4), the 
respiratory system (n = 2), the kidney (n=1), and other organ systems (n= 5). 35 
patients showed one symptom, 27 patients two symptoms, 10 patients three 
symptoms, two patients four symptoms, and one patient five symptoms. All 
signs and symptoms observed in the patients are listed in table 4. 
 
3.3.2 Analysis for individual plants 
An overview of the reported signs and symptoms in relation to the plants 
involved in all cases of ingestion of PFS or plants consumed as food can be 
accessed online as supplementary data (table B). 
 
3.4 Severe cases 
There were five severe cases (table 5); in three of these, a multi-ingredient PFS 
was involved. In a 72-year-old patient consuming Glycyrrhiza glabra L. and 
Mentha piperita L. as an infusion in a high dose, a hypertensive crisis and 
severe hypokalemia were observed. In another case, a 30-year-old man was 
using a product containing Citrus aurantium L., Camellia sinensis (L.) Kuntze, 
Paullinia cupana Kunth, and Coleus forskohlii (Willd.) Briq., which he combined 
with a product containing Rhodiola rosea L. to lose weight. He had a weight loss 
of 18 kg in two months, and suffered a myocardial infarction during sexual 
activity. He recovered completely. In a third case, a 40-year-old patient ingested 
a PFS containing Panax ginseng C.A.Mey., Paullinia cupana Kunth, Ilex 
paraguariensis A.St.-Hil., Lepidium meyenii Walp, Turnera diffusa Willd. ex 
Schult., Avena sativa L., and Capsicum sp. to increase his sexual potency. A 
few hours after the ingestion of a single recommended dose he suffered a 
transient ischemic attack (TIA). A rechallenge with the product provoked the 
recurrence of the transient ischemic attack, which resolved without specific 
treatment. In the two other cases, both patients showed a severe allergic 
reaction. 
 
 
4. Discussion 
In this study, adverse effects due to the ingestion of PFS or plants consumed as 
food seem to be infrequent issues for poisons centres; a finding that is 
supported by other studies. An analysis of calls involving the ingestion of a 
single medication reported to a poisons centre revealed that 3.4% were related 
to adverse drug reactions and of these only 4.7% were caused by the group of 
dietary supplements/herbals/homeopathics (Vassilev, 2009). In a prospective 
poisons centre study, only 0.4% of the calls concerned dietary supplements, of 
which 33% were due to adverse effects (Haller, 2008). Since the consumption 
of dietary supplements is wide-spread, it is plausible that adverse effects occur 
regularly, as has been recently shown by Geller et al. (Geller, 2015), but are 
probably detected only to a small extent by poisons centres or physicians. 
People not thinking of poisons centres as information source or not reporting 
their use of dietary supplements to the physician might explain these 
observations; this has been confirmed by other studies (Kennedy, 2005; Wu, 
2011). A study investigating the safety of phytomedicines (Cuzzolin, 2006), 
found that about half of the interviewed women attending an urban university 
hospital were consuming a PFS and 10% of them reported adverse effects. In 
62% the adverse effects were not communicated to the doctor. In addition, 
consumers might not be aware that they are suffering from adverse effects due 
to herbal supplements. 
This study analyzed two situations in which plant material was ingested: on the 
one hand the ingestion of a plant in form of a preparation (PFS) with the 
purpose to maintain health, and on the other, the consumption of a plant as 
food. Between these two situations there were considerable differences 
concerning the involved plants and, accordingly, the observed signs and 
symptoms. Consumption of plants as food mainly involved a single plant and 
caused gastrointestinal symptoms, allergic reactions, and electrolyte changes, 
whereas the ingestion of PFS involved many different symptoms due to the 
large diversity of plants and the concurrent ingestion of multiple plants. Although 
the two situations differ considerably, information about symptoms related to the 
ingestion of a single plant as food might give an indication about the possible 
toxicity of a PFS containing the same plant. 
In this study gastrointestinal and neurological symptoms were the clinical effects 
most frequently observed, which is in accordance with data from the Italian 
pharmacovigilance centre on spontaneously reported adverse effects related to 
natural health products (including homeopathics) (Menniti-Ippolito, 2008). Data 
on complementary medicines from pharmacovigilance centres in Sweden and 
Singapore showed different results. In the Singapore database mostly 
endocrine and nervous system disorders were recorded (Patel, 2012), whereas 
in Sweden skin and hypersensitivity reactions predominated (Jacobsson, 2009). 
Part of these differences can be explained by the type of institution which 
performed the study: pharmacovigilance centres focus on adverse reactions to 
drugs ingested in therapeutics doses, whereas poisons centres mostly deal with 
overdoses of drugs and other substances. The fact that skin reactions 
predominated among the adverse effects to natural health products in the 
Swedish study is in line with data from the WHO adverse drug reactions 
database, where skin reactions were the most frequently registered symptoms 
associated with the use of herbal medicines (Farah, 2000). In the Singapore 
study, many cases of adulteration (with pharmaceutical substances) were 
reported and the involved substances rather than the plants were responsible 
for the adverse effects (e.g. endocrine disorders). The quality of the involved 
plant material is a general issue when it comes to the use of PFS. Lack of 
standardization and contamination with other plants during preparation, together 
with no or poor quality control may lead to adverse effects in case of 
consumption (Soares Neto, 2013) and could have also contributed to the 
adverse effects observed in our study. 
Hepatotoxicity is an important issue when investigating the safety of 
medications, and many herbal medications do affect the liver (Bunchorntavakul, 
2013; Stickel, 2005; Teschke, 2012). Nevertheless, in this study there were only 
few reports of hepatotoxicity (4 of 75 cases), and this is in contrast to the 
literature. The plants associated with hepatic signs and symptoms in this study 
included Angelica archangelica L., Camellia sinensis (L.) Kuntze, Carum carvi 
L., Crithmum maritimum L., Dioscorea villosa L., Fucus vesiculosus L., Glycine 
max (L.) Merr., Hibiscus sabdariffa L., Mentha piperita L., and Opuntia ficus-
indica (L.) Mill.. Although reports and experimental studies on hepatotoxicity of 
Camellia sinensis (L.) Kuntze (Bunchorntavakul, 2013; Mazzanti, 2009), 
Dioscorea villosa L. (Wojcikowski, 2008), and Mentha piperita L. (Akdogan, 
2004) exist, the design of the present study does not allow to add further 
evidence, particularly if the plant was part of a multi-ingredient product. In 
addition, a causality assessment according to RUCAM (Roussel Uclaf Causality 
Assessment Method), which is the reference method for evaluating drug and 
herb induced liver injury (Danan, 2016), was not possible due to incomplete 
case information. This is for example the case for Dioscorea villosa L., which 
was involved in two of the four cases of hepatotoxicity. However, as the PFS 
included multiple ingredients and as some analytical data were missing, a 
definitive causal relationship could not be established. Nevertheless, this plant 
deserves particular attention and further investigation is warranted. 
Most cases in this study showed mild symptoms and a benign clinical course, 
which is consistent with other studies from poisons centres evaluating adverse 
effects related to herbal remedies and dietary supplements (Haller, 2008; Yang, 
2002), where most adverse effects were mild and severe outcomes were rare. 
In contrast, the adverse effects described in the Italian pharmacovigilance study 
were associated with a rather high need for hospitalization (Menniti-Ippolito, 
2008), an observation they explain by a greater attention to complete drug 
history in patients with serious reactions. In our study, there seemed to be more 
severe courses when a multi-ingredient PFS or a plant consumed as food were 
involved, as compared to the ingestion of a single-ingredient PFS. The 
symptoms most commonly recorded in the moderate cases of this study were - 
apart from unspecific gastrointestinal symptoms - edema and hypokalemia, 
sometimes accompanied by hypertension or ECG changes. In all of these 
cases Glycyrrhiza glabra L. was involved. These observations correspond well 
to the known effects of the plant, which affects the electrolyte balance 
(Isbrucker, 2006; Olukoga, 2000). 
The plant most commonly involved in cases of adverse effects related to the 
ingestion of PFS or plants consumed as food was Valeriana officinalis L.. The 
adverse reactions most frequently observed with this plant in this study, i.e. 
somnolence, drowsiness, and gastrointestinal symptoms, are also described in 
the literature (Taibi, 2007), and the neurological symptoms are very well 
explained by valerian’s properties as relaxant and sleep aid. Valerian was 
usually the only component of the PFS ingested. This suggests a probable 
causal relationship between the symptoms and the plant. 
Products containing widely-used plants for weight loss such as Camellia 
sinensis (L.) Kuntze, Ephedra distachya L., Hoodia gordonii (Masson) Sweet ex 
Decne., Citrus aurantium L., Garcinia cambogia (Gaertn.) Desr. were only rarely 
recorded, although they are marketed as highly effective. Reasons for this 
observation might be the poor availability in shops due to legal restrictions 
based on their negative safety profile or the fear of serious side effects (i.e. 
cardiotoxicity), which are known for some of these plants (Vitalone, 2011). 
Some other plants reported to be most frequently used as supplements in the 
literature, including Panax ginseng C.A.Mey., Echinacea sp., Ginkgo biloba L., 
Hypericum perforatum L., Allium sativum L., and Serenoa repens (W.Bartram) 
Small (Kennedy, 2005; Marinac, 2007; Wu, 2011), were only rarely involved in 
the cases of this study. The same is true for plants contained in supplements 
enhancing athletic performance and aphrodisiacs (e.g. Coleus forskohlii (Willd.) 
Briq., Schisandra chinensis (Turcz.) Baill., Tribulus terrestris L., Pausinystalia 
yohimbe (K.Schum.) Pierre ex Beille, Epimedium grandiflorum C.Morren, 
Trigonella foenum-graecum L., Lepidium meyenii Walp, Turnera diffusa Willd. 
ex Schult.) (Rowland, 2003). This may be due to the fact that some products 
containing these plants are classified as pharmaceuticals and not as PFS and 
were therefore not included in the study. 
 
Limitations 
The interpretation of the findings of this study is mainly limited by the 
retrospective nature of the study design with the related incompleteness of data 
and lack of uniform data classification. This is for example the case for the 
ingested dose of a PFS or a plant, which could not always be recorded or 
specified in detail. In addition, this is the reason why causality assessment of 
hepatotoxicity cases according to RUCAM (Danan, 2016) was not possible. 
A further limitation is related to the object of the study and to the fact that there 
is a lack of uniform categorization of PFS among different countries. The legal 
status of a herbal preparation depends on the law of the specific country, 
meaning that a preparation can be classified as a supplement in one country, as 
a (traditional) medicinal product in another, and as a pharmaceutical in a third 
one (Egan, 2011; Silano, 2011). Also the wide range of different terminology 
used for PFS, which are interchangeably referred to in the literature as ‘‘plant 
foods’’, ‘‘plant extracts’’, ‘‘botanicals’’, ‘‘herbals’’ and/or ‘‘herbs’’ (Egan, 2011) 
adds to the complexity of the subject. 
Furthermore, it is known from the literature that data from poisons centres are 
subject to reporting bias (Hoffman, 2007) and it is plausible that delayed effects 
and chronic toxicity were underrepresented. It is also known that patients tend 
to underreport the use of PFS and the magnitude of their use is 
underrecognized by physicians (Cuzzolin, 2006; Kennedy, 2005; Wu, 2011). In 
addition, our strict inclusion criteria led to small case numbers, especially for 
some PFS/plants. However, we are convinced that these restrictions were 
necessary to be able to interpret the findings properly. Due to the limited 
number of cases involving children, the results regarding this population should 
be interpreted with particular caution. 
The fact that a large diversity of plants was involved in many documented cases 
with adverse effects is an important limitation regarding the risk assessment of 
single plants and the establishment of a causal relationship between a plant and 
an adverse effect. 
 
 
5. Conclusions 
PFS-related adverse effects seem to be relatively infrequent issues for poisons 
centres and most cases in this study showed mild symptoms and a benign 
clinical course. Nevertheless, the occurrence of some severe adverse effects 
and the increasing popularity of PFS together with the issue of underreporting, 
require continuous active surveillance, especially of possible vulnerable groups 
such as the elderly. Further research is warranted to validate the preliminary 
results of this study, and a multidisciplinary approach with an international 
perspective should be prioritized. 
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Table 1: Severity of signs and symptoms according to PSS in 
relation to patients’ characteristics, and the product (PFS/plant). 
For PFS, the number of ingredients is reported (multi: >1 
ingredient, mono: 1 ingredient). 
SEVERITY
Minor Moderate Severe Total
PATIENT     
Adult 50 13 5 68
  Female 27 10 37
  Male 23 3 5 31
Child 6 1 0 7
  Female 3 1 4
  Male 3 3
Total 56 14 5 75
PRODUCT     
PFS 45 8 4 57
  Multi 18 6 3 27
  Mono 27 2 1 30
Plant 11 6 1 18
Total 56 14 5 75
 
  
Table 2: The 15 plants (as ingredients of PFS or consumed as food) involved in three or more 
cases of adverse effects. (Caffeine is listed because it is a relevant ingredient in many PFS and 
often it is added to increase the caffeine content of the product) 
 
Plant / Ingredient     
Latin name Common name As Food In PFS Total 
Valeriana officinalis L. Valerian 1 22 23 
Camellia sinensis (L.) Kuntze Green tea 1 9 10 
Melissa officinalis L. Lemon balm  7 7 
Mentha piperita L. Peppermint  7 7 
Passiflora incarnata L. Passionflower 1 6 7 
Paullinia cupana Kunth Guarana  7 7 
Glycyrrhiza glabra L. Licorice 5 1 6 
Ilex paraguariensis A.St.-Hil. Yerba mate  6 6 
Caffeine   5 5 
Panax ginseng C.A.Mey. Ginseng  5 5 
Citrus aurantium L. Bitter orange  4 4 
Cynara scolymus L. Artichoke 4  4 
Dioscorea villosa L. Wild yam  4 4 
Allium ursinum L. Wild garlic 3  3 
Carum carvi L. Caraway  3 3 
Taraxacum officinale L. Common dandelion 2 1 3 
 
 
  
Table 3: Severity of signs and symptoms in relation to all 58 different plants consumed as 
ingredients of PFS or as food with the corresponding number of cases. 
 
Plant / Ingredient  Severity 
Latin name Common name Family Minor Moderate Severe Total
Achyranthes aspera L. Prickly chaff 
flower 
Amaranthaceae 1 1
Aesculus hippocastanum L. Horse chestnut Sapindaceae 1  1
Allium ursinum L. Wild garlic Amaryllidaceae 3  3
Aloe vera (L.) Burm.f. Aloe Xanthorrhoeaceae 1  1
Ananas comosus (L.) Merr. Pineapple Bromeliaceae 1 1
Angelica archangelica L. Garden angelica Apiaceae 2 2
Areca catechu L. Betel nut tree Arecaceae 1 1
Avena sativa L. Oat Poaceae  1 1
Caffeine   5  5
Camellia sinensis (L.) Kuntze Green tea Theaceae 6 3 1 10
Capsicum annuum L. Pepper Solanaceae 1 1 2
Capsicum sp. Peppers Solanaceae  1 1
Carum carvi L. Caraway Apiaceae 1 2 3
Cassia angustifolia M.Vahl Tinnevelly 
senna 
Leguminosae 2  2
Citrus aurantium L. Bitter orange Rutaceae 3  1 4
Citrus limon (L.) Osbeck Lemon Rutaceae 1  1
Citrus sp. Citrus fruit Rutaceae 1  1
Cola nitida (Vent.) Schott & 
Endl. 
Kola nut Malvaceae 1 1 2
Coleus forskohlii (Willd.) Briq. Indian coleus Lamiaceae 1  1 2
Commiphora mukul (Hook. ex 
Stocks) Engl. 
Guggul Burseraceae 1 1
Crataegus monogyna Jacq. Common 
hawthorne 
Rosaceae 1  1
Crithmum maritimum L. Sea fennel Apiaceae 2 2
Cuminum cyminum L. Cumin Apiaceae 1  1
Cynara scolymus L. Artichoke Compositae 3  1 4
Dioscorea villosa L. Wild yam Dioscoreaceae 4 4
Echinacea pallida (Nutt.) Nutt. Pale purple 
coneflower 
Compositae 2  2
Eleutherococcus senticosus 
(Rupr. & Maxim.) Maxim. 
Siberian ginseng Araliaceae 1 1
Ephedra sp. Ephedra / Ma 
Huang 
Ephedraceae 1  1
Fucus vesiculosus L. Bladderwrack Fucaceae 2 2
Garcinia sp. Garcinia Clusiaceae 1  1
Ginkgo biloba L. Ginkgo  Ginkgoaceae 2 2
Glycine max (L.) Merr. Soybean Leguminosae 1  1 2
Glycyrrhiza glabra L. Licorice Leguminosae 1 4 1 6
Harpagophytum procumbens 
(Burch.) DC. ex Meisn. 
Devil's claw Pedaliaceae 1  1
Hibiscus sabdariffa L. Roselle Malvaceae 2 2
Hypericum perforatum L. St. John's wort Hypericaceae 1  1
Ilex paraguariensis A.St.-Hil. Yerba mate Aquifoliaceae 4 1 1 6
Illicium verum Hook f. Star anise Schisandraceae 1  1
Lepidium meyenii Walp Maca Brassicaceae  1 1
Melissa officinalis L. Lemon balm Lamiaceae 7  7
Mentha piperita L. Peppermint Lamiaceae 6  1 7
Ocimum basilicum L. Basil Lamiaceae 1  1
Opuntia ficus-indica (L.) Mill. Prickly pear 
cactus 
Cactaceae 2 2
Panax ginseng C.A.Mey. Ginseng Araliaceae 3 1 1 5
Passiflora incarnata L. Passionflower Passifloraceae 7  7
Paullinia cupana Kunth Guarana Sapindaceae 4 1 2 7
Pausinystalia yohimbe 
(K.Schum.) Pierre ex Beille 
Yohimbe Rubiaceae 1  1
Piper nigrum L. Black pepper Piperaceae 1  1
Punica granatum L. Pomegranate Lythraceae 1  1
Rhamnus purshianus DC. Cascara 
buckthorn 
Rhamnaceae 1  1
Rhodiola rosea L. Golden root Crassulaceae  1 1
Salix alba L. White willow Salicaceae 2  2
Taraxacum officinale (L.) 
Weber ex F.H.Wigg 
Common 
dandelion 
Compositae 1 2 3
Theobroma cacao L. Cocoa tree Malvaceae 1  1
Turnera diffusa Willd. ex 
Schult. 
Damiana Passifloraceae  1 1
Vaccinium myrtillus L. Common 
bilberry 
Ericaceae 1  1
Valeriana officinalis L. Valerian Caprifoliaceae 23  23
Vitis vinifera L. Grape vine Vitaceae 1 1 2
Withania somnifera (L.) Dunal Indian ginseng Solanaceae 1 1
Total  106 39 16 161
 
Table 4: Observed signs and symptoms in the 75 patients with adverse effects after the 
ingestion of a PFS or a plant as food. 
Signs / symptoms N  Signs / symptoms N
Nervous system   Skin / Mucosa  
Drowsiness 16  Skin or mucosa irritation 5 
Somnolence 8  Angioedema 2 
Dizziness 7  Urticaria 2 
Headache 5  Liver  
Restlessness 2  Hepatitis 3 
Tremor 2  Elevated liver enzymes 1 
Transient ischemic attack 1  Icterus 1 
Gastrointestinal system   Respiratory system  
Nausea 14  Respiratory insufficiency 2 
Vomiting 14  Kidney  
Abdominal pain 13  Renal insufficiency 1 
Diarrhea 11  Other  
Cardiovascular system   Hypokalemia 3 
Tachycardia 5  Edema 2 
Hypertension 4  Miosis 1 
ECG changes 3    
Chest pain 2    
Hypotension 1    
Myocardial infarction 1    
 
  
Table 5: Plants/PFS involved and signs/symptoms observed in the five severe cases 
Case Age / 
Gender  
Plant / PFS Product
form 
Quantity Duration 
of use 
Latency of
symptoms 
Symptoms Causality
1 72 y/o 
male 
Glycyrrhiza glabra 
L., Mentha piperita 
L. 
Tea 8 tea  
bags/ d 
3 months 1 months; 
hospitaliza-
tion after 3 
months 
Disorientation; 
Hypertensive crisis 
(210/90 mm Hg) 
and severe hypo-
kalemia (1.7 
mEq/L) 
Probable 
2 30 y/o 
male 
Citrus aurantium 
L., Camellia 
sinensis (L.) 
Kuntze, Paullinia 
cupana Kunth, 
Coleus forskohlii 
(Willd.) Briq., 
Rhodiola rosea L. 
Capsules 
and tablets 
(Rhodiola 
rosea) 
Unknown > 2 months Unknown Myocardial 
infarction 
Probable; 
unlikely for 
Rhodiola 
rosea 
3 40 y/o 
male 
Avena sativa L., 
Capsicum sp., Ilex 
paraguariensis 
A.St.-Hil., 
Lepidium meyenii 
Walp, Panax 
ginseng C.A.Mey., 
Paullinia cupana 
Kunth, Turnera 
diffusa Willd. ex 
Schult. 
Tablets 4 tablets Once Few hours Transient ischemic 
attack  
Certain 
(positive 
rechallenge) 
4 57 y/o 
male 
Glycine max (L.) 
Merr. 
Soybean 
powder 
(Herbalife®) 
diluted in 
soybean 
milk 
1 glass 9 days 30 min after 
last 
exposure 
Angioedema Certain 
(positive 
rechallenge) 
5 41 y/o 
male 
Cynara scolymus 
L. 
Artichoke 
as food 
Unknown Once 10 min Anaphylaxis Probable 
 
